Research Topics
| David J GrahamSummaryAffiliation: Food and Drug Administration Country: USA Publications
|
Detail Information
Publications
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazoneDavid J Graham
Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room 4314, Silver Spring, MD 20993 0002, USA
JAMA 304:411-8. 2010..Studies have suggested that the use of rosiglitazone may be associated with an increased risk of serious cardiovascular events compared with other treatments for type 2 diabetes...- Cardiovascular and mortality risks in Parkinson's disease patients treated with entacaponeDavid J Graham
Office of Epidemiology and Surveillance, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
Mov Disord 28:490-7. 2013..09; 95% CI, 0.98-4.45) or absence (HR, 0.51; 95% CI, 0.27-0.95) of advanced PD-related morbidities (P value for interaction=0.004). Entacapone was not associated with an increased risk of AMI, stroke, or death in elderly patients with PD... 
Troglitazone-induced liver failure: a case studyDavid J Graham
Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, HFD 400, Room 15B 32, Rockville, MD 20857, USA
Am J Med 114:299-306. 2003..We evaluated the clinical features of all cases reported to the Food and Drug Administration and estimated the duration and magnitude of the risk of liver failure associated with continued use of the drug...- Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugsTarek A Hammad
Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, MD 20993 0002, USA
Pharmacoepidemiol Drug Saf 17:315-21. 2008.... - Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugsDavid J Graham
Office of of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
JAMA 292:2585-90. 2004..Lipid-lowering agents are widely prescribed in the United States. Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents are not available... - Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination SurveyStephen R Benoit
Food and Drug Administration, Rockville, Maryland, USA
Eur J Cardiovasc Prev Rehabil 12:363-8. 2005..CONCLUSIONS: Healthcare practitioners should be aware that a prolonged QTc interval is a potential indicator of cardiovascular risk, and should exercise caution in prescribing potentially QT-prolonging medications to certain patients... - Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazoneDavid J Graham
Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
Am J Gastroenterol 98:175-9. 2003..3, 1385). CONCLUSIONS: Troglitazone use was associated with a marked increase in risk of hospitalized acute idiopathic liver injury and ALF... - Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control studyDavid J Graham
Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA
Lancet 365:475-81. 2005.... - Peripheral neuropathy in patients treated with leflunomideRenan A Bonnel
Office of Drug Safety, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857, USA
Clin Pharmacol Ther 75:580-5. 2004..Our objective was to describe the clinical features, time course, and outcome of new-onset peripheral neuropathy occurring in patients treated with leflunomide...